Startups
Vedana Therapeutics develops precision small-molecule therapies that modulate protein homeostasis pathways to treat neurodegenerative diseases.
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 22, 2026 | Nura Bio Raises $73.8M in Series B Funding | Nura Bio Inc., South San Francisco, CA-based clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, raised $73.8M in Series B funding. The round was led by The Column Group, with participation from Euc... |
| Jun 19, 2026 | Vedana Therapeutics Raises $46 Million To Advance Next-Generation Migraine Therapies | Vedana Therapeutics emerged from stealth with $46 million in Series A funding to advance next-generation therapies for migraine prevention. The funding round was co-led by Westlake BioPartners and Canaan Partners, with participation from Da... |
| Jun 17, 2026 | Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies | Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention. The financing was co-led by Westlake BioPartners and Canaan Pa... |
| Vedana Therapeutics |
Reviews 0
FAQ about Vedana Therapeutics, Inc.
What has the press written about Vedana Therapeutics, Inc.?
Parsers VC has collected 5 articles mentioning Vedana Therapeutics, Inc., among them “Nura Bio Raises $73.8M in Series B Funding” (Jun 22, 2026) and “Vedana Therapeutics Raises $46 Million To Advance Next-Generation Migraine Therapies” (Jun 19, 2026).
Is Vedana Therapeutics, Inc. still active?
Yes, Vedana Therapeutics, Inc. is active; its latest activity on Parsers VC dates from Jul 10, 2026.